Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares Outstanding
Ratios

Tvardi Therapeutics (TVRD) Receivables - Net (2021 - 2025)

Tvardi Therapeutics' Receivables - Net history spans 6 years, with the latest figure at $1.2 million for Q1 2025.

  • On a quarterly basis, Receivables - Net fell 28.46% to $1.2 million in Q1 2025 year-over-year; TTM through Mar 2025 was $1.2 million, a 28.46% decrease, with the full-year FY2024 number at $407000.0, down 85.28% from a year prior.
  • Receivables - Net hit $1.2 million in Q1 2025 for Tvardi Therapeutics, up from $407000.0 in the prior quarter.
  • Over the last five years, Receivables - Net for TVRD hit a ceiling of $20.0 million in Q3 2021 and a floor of $359000.0 in Q2 2024.
  • Historically, Receivables - Net has averaged $3.5 million across 5 years, with a median of $1.8 million in 2021.
  • Biggest five-year swings in Receivables - Net: fell 15.18% in 2023 and later plummeted 87.02% in 2024.
  • Tracing TVRD's Receivables - Net over 5 years: stood at $20.0 million in 2021, then tumbled by 83.73% to $3.3 million in 2022, then fell by 15.18% to $2.8 million in 2023, then crashed by 85.28% to $407000.0 in 2024, then soared by 201.97% to $1.2 million in 2025.
  • Business Quant data shows Receivables - Net for TVRD at $1.2 million in Q1 2025, $407000.0 in Q4 2024, and $435000.0 in Q3 2024.